AXSM Stock Chart & Stats
$1519.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1519.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,519.00 - $1,519.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$141.83B
Enterprise Value$12.58B
Total Cash (Recent Filing)$319.85M
Total Debt (Recent Filing)$219.21M
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 02, 2026EPS Estimate
-11.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding52,380,817
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)102.90
Price to Sales (P/S)14.23
P/FCF Ratio-96.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5,336.87Price Target Upside251.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-54.19
Revenue Forecast (FY)$17.75B
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthRapid revenue expansion across AUVELITY, SUNOSI, and SYMBRAVO indicates increasing commercial scale and product adoption. Sustained growth can improve operating leverage, support broader reinvestment, and strengthen Axsome’s position in CNS therapeutics over the next several quarters.
Broad CNS PipelineA broad late-stage CNS pipeline creates multiple opportunities to extend the commercial portfolio beyond current products. Progress across several indications may diversify future revenue sources and provide repeated regulatory and launch catalysts over the medium term.
Improving Operating LeverageExpenses growing more slowly than revenue is an encouraging sign that Axsome’s commercial platform can scale more efficiently. If this relationship persists as launches mature, it could gradually narrow operating losses and improve the company’s path toward profitability.
Bears Say
Persistent Operating LossesAxsome remains materially unprofitable despite strong revenue growth, showing that commercial expansion has not yet translated into sustainable earnings. Continued losses can constrain internal funding capacity and leave results sensitive to the timing and success of future launches.
Negative Cash GenerationOngoing negative operating and free cash flow means Axsome is still consuming cash to fund its operations and development programs. Although burn has improved, the business remains dependent on its liquidity and financing capacity until cash generation becomes consistently positive.
Elevated LeverageDebt remains high relative to the company’s equity base, reducing financial flexibility while Axsome is still loss-making. Leverage can increase pressure on future cash allocation and make it harder to absorb execution setbacks before profitability and equity capital strengthen.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $1519.00 and its highest was $1519.00 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $141.83B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Nov 02, 2026 which is in 8 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -$18.482 earnings per share for the quarter, missing the consensus estimate of -$16.652 by -$1.83.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -11.61.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 52,380,817 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$18.482 in its last earnings report, missing expectations of -$16.652. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in MX:AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5,336.87 (251.34% Upside)
$5,336.87 (251.34% Upside)
Blogger Sentiment
Bullish
MX:AXSM Sentiment 77%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.15%
12-Months-Change
Fundamentals
Return on Equity
-255.60%
Trailing 12-Months
Asset Growth
19.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum across Axsome’s commercial portfolio, with 46% revenue growth, accelerating AUVELITY demand, encouraging early Alzheimer’s disease agitation launch metrics, continued SYMBRAVO and SUNOSI prescription growth, improving payer coverage, and substantial pipeline progress. The company remains loss-making, reported higher SG&A and ongoing cash burn, and acknowledged that several Alzheimer’s disease agitation launch metrics are still early and limited. Overall, the highlights significantly outweighed the lowlights.View all MX:AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$5,336.87
▲(251.34% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Jazz Pharmaceuticals
―
Neurocrine
―
Harmony Biosciences Holdings
―
Biohaven Ltd.
―